Home / Resource Library / A Probabilistic Cost‑Effectiveness Analysis of Venetoclax and Obinutuzumab as a First‑Line Therapy in Chronic Lymphocytic Leukemia in Canada
A Probabilistic Cost‑Effectiveness Analysis of Venetoclax and Obinutuzumab as a First‑Line Therapy in Chronic Lymphocytic Leukemia in Canada